metastatic hormone-sensitive prostate cancer (mhspc)
Published 1 year ago • 730 plays • Length 3:51Download video MP4
Download video MP3
Similar videos
-
6:53
perspectives on metastatic hormone-sensitive prostate cancer | bayer
-
13:09
pca commentary: metastatic hormone sensitive prostate cancer (mhspc): many treatment options
-
2:25
subgroups of metastatic hormone-sensitive prostate cancer (mhspc)
-
7:48
new treatment option for metastatic hormone-sensitive prostate cancer
-
1:06:24
metastatic hormone sensitive prostate cancer
-
1:01:45
metastatic hormone sensitive prostate cancer: expert guidance for urologists
-
16:26
patient selection in metastatic hormone-sensitive prostate cancer (mhspc)
-
1:18:13
urowebinar: paradigm shifts in metastatic hormone sensitive prostate cancer mhspc recent treatment
-
17:44
new approaches to metastatic hormone sensitive prostate cancer
-
34:25
treatment options for the management of metastatic hormone-sensitive prostate cancer (mhspc)
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
48:10
urowebinar: paradigm shifts in metastatic hormone sensitive prostate cancer: recnt treatmnt dvlpmnts
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer
-
4:05
evaluating triplet therapy in metastatic hormone sensitive prostate cancer
-
1:56
arasens: dialuramide plus adt and docetaxel for metastatic hormone-sensitive prostate cancer
-
3:15
life with prostate cancer
-
2:27
triplet therapy for metastatic hormone-sensitive prostate cancer
-
1:36
fda approves bayer's nubeqa (darolutamide) for non-metastatic castration-resistant prostate cancer
-
2:29
dr choudhury on survival advantages with ar pathway inhibitors in mhspc